Summary of findings from the study and speculations from previous research. (Nishiwaki et al., npj Parkinson's Disease, 2024) ...

Two years ago, Sharon Chakkalackal of Toronto, Ont., was given a diagnosis she never expected — young-onset Parkinson’s ...

Pathogenic mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson’s disease. 1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of ...

Brett Favre has opened up about living with Parkinson’s disease, saying he often wakes up feeling as stiff as “a board.” The ...

Blarcamesine’s safety profile indicates not requiring routine MRI monitoring, and the advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and ...

New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.

SPR301 is a potential best-in-class gene therapy candidate that delivers a more stable, rationally engineered version of GCase, the enzyme ...

The Movers and Shakers podcast host on how his Battersea rescue dog Derek the spaniel helped 'discover' his neurological ...

Parkinson's drug, entacapone, induces iron deficiency, which alters the gut microbiome and triggers the growth of bacteria ...